A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
In this special series, we explore the state of select public companies operating in a particularly intriguing area of life sciences. This week, we look at metastatic cancer, an area of significant unmet need. These companies, including OncoSec Medical, are having success with their innovative approaches to treating metastatic cancer, and are seeing results in their performance int he public markets.
The fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by UV exposure or excessive sun burn.
Provectus Pharmaceuticals Uses Old Drug To Actualize Novel Therapeutics for Cancer and Skin Disorders
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
Advanced Life Sciences (OTC BB: ADLS) took two steps this week toward advancing its lead drug candidate, Restanza.
Doctors in London successfully used a genetically engineered version of the herpes virus to treat head and neck cancer in a small clinical trial of 17 patients.